News

The PD2i Analyzer uses Vicor’s patented, proprietary point correlation dimension algorithm (PD2i), a deterministic, non-linear measure that analyzes ECG data to risk stratify target populations as to future

The final value of the MDS Pharma Services goodwill write-down, previously estimated to be in the range of $270 million to $370 million, is $320 million. Including the

The National Cancer Centre of Singapore (NCCS) said that it selected nimotuzumab because of its reported preferential safety profile compared with other epidermal growth factor receptor (EGFR)-targeting cancer

The company will conduct a Phase II trial in approximately 128 patients with non-small cell lung cancer (NSCLC) and a Phase II trial in approximately 88 patients with

Most recently serving as vice president of global sales and service and vice president of marketing and R&D. He has also held several senior marketing and product management

The Phase I/IIa trial is designed to assess the safety, tolerability and biological activity of the vaccine. CureVac expects to start the treatment of the first patient in

In his last position, he was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Before that, Schmidt served

The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and pharmacokinetic properties of CX-4945 and to select the appropriate dose for Phase II

The company has also experienced a reorder rate of over 90%. “The promise of personalized medicine is quickly becoming a reality for patients with lung and colon cancer